These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27654746)

  • 21. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].
    Wu NQ; Li JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):444-446. PubMed ID: 28511335
    [No Abstract]   [Full Text] [Related]  

  • 27. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.
    Eisen A; Giugliano RP
    Curr Opin Cardiol; 2016 Nov; 31(6):644-653. PubMed ID: 27661220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.
    Packard CJ
    Circulation; 2017 Jan; 135(4):363-365. PubMed ID: 28115413
    [No Abstract]   [Full Text] [Related]  

  • 30. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook.
    Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ
    BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
    Milionis H; Liamis G; Elisaf M
    Expert Opin Biol Ther; 2015 Feb; 15(2):287-98. PubMed ID: 25491324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
    Cao YX; Li JJ
    Diabetes Care; 2018 Apr; 41(4):e69. PubMed ID: 29559466
    [No Abstract]   [Full Text] [Related]  

  • 33. Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.
    de Carvalho LSF; Campos AM; Sposito AC
    Diabetes Care; 2018 Apr; 41(4):e70-e71. PubMed ID: 29559467
    [No Abstract]   [Full Text] [Related]  

  • 34. Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres.
    Kohli M; Patel K; MacMahon Z; Ramachandran R; Crook MA; Reynolds TM; Wierzbicki AS
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28994502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
    Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
    Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
    Strat AL; Ghiciuc CM; Lupuşoru CE; Mitu F
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):228-32. PubMed ID: 27483697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
    Page MM; Stefanutti C; Sniderman A; Watts GF
    Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.